Combination cancer immunotherapies tailored to the tumour microenvironment.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentUpdate on immune checkpoint inhibitors in gynecological cancersPriming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Molecular and genetic inflammation networks in major human diseases.Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapyAnti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.Radiotherapy: Changing the Game in Immunotherapy.Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity.Worldwide malaria incidence and cancer mortality are inversely associated.The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.Challenges faced when identifying patients for combination immunotherapy.Atezolizumab for the treatment of non-small cell lung cancer.Combinatorial drug delivery approaches for immunomodulation.Is autoimmunity the Achilles' heel of cancer immunotherapy?Longitudinal microcomputed tomography-derived biomarkers for lung metastasis detection in a syngeneic mouse model: added value to bioluminescence imaging.Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.Emerging role of checkpoint blockade therapy in lymphoma.Emerging Opportunities and Challenges in Cancer Immunotherapy.Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.Microfluidic models for adoptive cell-mediated cancer immunotherapiesTargeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.Immunoregulatory functions of VISTA.Neutrophils in cancer.Genomic Approaches to Understanding Response and Resistance to Immunotherapy.Immuno-Oncology: The Third Paradigm in Early Drug Development.Targeting cancer-related inflammation in the era of immunotherapy.Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.
P2860
Q26738359-3857F547-6F0F-4496-98D7-B2251BDE244BQ28076497-CA806BF4-718C-4058-9917-535DD9C8617CQ30360210-E8199982-0C90-44B9-B99C-23651A137119Q31137039-9E5EA0A6-768D-4E0E-B2BF-E000A4A30D12Q33839204-A74ED252-DD1D-4CCC-9D0E-06DDF1A2F209Q36140389-1008963F-5C0B-45DE-A993-BD9ED8AC266AQ37079141-FA9A71F3-46F9-4DB3-8BEA-A7C7CC4CB450Q37114392-90F9F7B7-AF32-4F9D-8F0A-2DB1A94375E8Q37195052-BACBE464-8527-4AF4-A112-098DFE96C533Q37222143-66953E15-8566-4057-9A1C-D0BCE47D06EDQ37351338-28E16014-49C6-406F-800C-3C0B68E1F5F7Q37469720-CA3B4E79-940B-4D9B-AEFD-C620F77C8B6DQ37545879-D28D2D3A-B8F8-47B5-88FD-296F73CE9FCEQ37554718-45A975CF-3696-4DCE-A5C1-C99A2B93DB19Q37616487-976FA39D-EFD6-4057-81FC-8E5638ADA621Q37625551-636969E2-C949-4233-A604-2EF7186EB572Q37640572-8392F76F-D6F8-488A-BB66-FB80A3949FA0Q37695311-2DE1C552-FC6D-4814-9C03-B531DB6C8B0FQ37709496-C0EDAA50-6E0A-487F-B81F-0238198DEB89Q38621231-7E9AAB93-6D74-4FB0-ABA5-5E0CDF0648A2Q38638046-4A7196E7-BC59-4DC9-BBCC-430FD93085E5Q38675969-A584FE29-EFA6-4074-B2A1-1A3FBD20C69EQ38680602-B6733184-CA4C-49F0-88E2-3CE5BF42DD98Q38687375-A167C5DF-785C-45E3-81AD-8BD6C3F2EA98Q38729880-4ED879E2-85BF-4407-8896-7693DCE552DAQ38751328-8C2221D3-8EEA-4D00-A3A0-00A305A851B4Q38753142-178EAE3A-FB49-446C-8C81-0EE241430BDCQ38756923-670ADD5D-93BF-4EAB-9E2C-8D3BF5D2EB27Q38809772-21A22B24-12F2-4874-838C-6EEDFDB96B56Q38830663-9CF06538-1E40-4BFB-BA52-CEF412F46BB4Q38835747-8F5F15C2-AA5E-4C59-A13F-858303F876DDQ38875021-DD14171B-C330-4791-9D00-01E556A19410Q38878893-C159883D-B41D-4B5D-9643-9EF21EF4688DQ38930123-45B79059-F40E-4870-BF9B-AB8215ECA924Q38936555-927A4023-F172-4422-A794-9A2C63465CDBQ38971262-AF237E79-6447-4F3B-9469-5CB9D2B24D37Q39044147-172C1E87-ACDE-4BB9-B41C-FE2DAA713696Q39044981-1CC706C1-2BA5-4CFE-AC93-BD3A69C45D72Q39255886-A9162CCD-8FEE-442A-B485-2F976A9F0939Q39294187-16466CA7-3C20-4518-8E05-8377A5951CFC
P2860
Combination cancer immunotherapies tailored to the tumour microenvironment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Combination cancer immunotherapies tailored to the tumour microenvironment.
@en
type
label
Combination cancer immunotherapies tailored to the tumour microenvironment.
@en
prefLabel
Combination cancer immunotherapies tailored to the tumour microenvironment.
@en
P2093
P2860
P1476
Combination cancer immunotherapies tailored to the tumour microenvironment.
@en
P2093
Antoni Ribas
Michele W L Teng
Shin Foong Ngiow
P2860
P304
P356
10.1038/NRCLINONC.2015.209
P407
P577
2015-11-24T00:00:00Z